The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Postnatal Phencyclidine Administration Selectively Reduces Adult Cortical Parvalbumin-Containing Interneurons
Abstract
Transient postnatal NMDA receptor blockade by phencyclidine (PCP), ketamine, or MK-801 induces developmental neuroapoptosis and adult behavioral deficits, which resemble abnormal human behaviors typically present in schizophrenia. This study tested the hypothesis that PCP-induced developmental apoptosis causes a specific deficit of GABAergic interneurons containing parvalbumin (PV), calretinin (CR), or calbindin (CB). Young adult (PND56) rats that were given a single dose of PCP (10 mg/kg) on PND7 exhibited no densitometric change of either CR or CB neurons in any brain region studied, but demonstrated a selective deficit of PV-containing neurons in the superficial layers (II-IV) of the primary somatosensory (S1), motor (M), and retrosplenial cortices, but not in the striatum (CPu) or hippocampus. Further, CR and CB neurons, which were expressed at the time of PCP administration, showed no colocalization with cellular markers of apoptosis (terminal dUTP nick-end labeling (TUNEL) of broken DNA or cleaved caspase-3), indicating that CR- and CB-containing neurons were protected from the toxic effect of PCP and survived into adulthood. This suggests that the deletion of PV neurons occurred during development, but cleaved caspase-3 showed no colocalization with BrdU, a specific marker of S-phase proliferation. These data suggest that the loss of PV-containing neurons was not due to an effect of PCP on proliferating neurons, but rather an effect on post-mitotic neurons. The developmental dependence and neuronal specificity of this effect of PCP provides further evidence that this model may be valuable in exploring the pathophysiology of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, PVI are especially vulnerable to NMDAR hypofunction during development (Abekawa et al., 2007; Powell et al., 2012; Wang et al., 2008; Wang et al., 2013).”
From Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? (2016) · cites this paper as Wang et al., 2008
In the citing paper
“early postnatal PCP reduces the number of adult PVþ neurons in the PFC.58”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [58]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Meta-analysis of regional brain volumes in schizophrenia
Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W. R., David, A. S., Murray, R. M., & Bullmore, E. T. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.16 · Cited by 1,662
Ethanol Inhibits NMDA-Activated Ion Current in Hippocampal Neurons
Lovinger, D. M., White, G., & Weight, F. F. (1989) · Science · doi:10.1126/science.2467382 · Cited by 1,448
Ethanol-Induced Apoptotic Neurodegeneration and Fetal Alcohol Syndrome
Ikonomidou, C., Bittigau, P., Ishimaru, M. J., Wozniak, D. F., Koch, C. A., Genz, K., Price, M. T., Stefovska, V. G., Hörster, F., Tenkova, T., et al. (2000) · Science · doi:10.1126/science.287.5455.1056 · Cited by 1,382
Calcium-binding proteins in the nervous system
Baimbridge, K. G., Celio, M. R., & ROGERS, J. H. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90081-i · Cited by 1,329
Cited by
Sorted by citations
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Neill, J. C., Barnes, S. A., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 541
GABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414
Steullet, P., Cabungcal, J.-H., Coyle, J., Didriksen, M., Gill, K., Grace, A. A., Hensch, T. K., LaMantia, A.-S., Lindemann, L., Maynard, T. M., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.47 · Cited by 360
Kann, O., Papageorgiou, I. E., & Draguhn, A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.104 · Cited by 295
Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
Kehrer, C. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.006.2008 · Cited by 287
The interneuron energy hypothesis: Implications for brain disease
Kann, O. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.005 · Cited by 270
Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262
Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia
Behrens, M. M., Ali, S. S., & Dugan, L. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4457-08.2008 · Cited by 241
Multiple origins of the cortical gamma rhythm
Whittington, M. A., Cunningham, M. O., LeBeau, F. E. N., Racca, C., & Traub, R. D. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20814 · Cited by 253
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 225
Involvement of NOX2 in the Development of Behavioral and Pathologic Alterations in Isolated Rats
Schiavone, S., Sorce, S., Dubois-Dauphin, M., Jaquet, V., Colaianna, M., Zotti, M., Cuomo, V., Trabace, L., & Krause, K.-H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.033 · Cited by 208
Steullet, P., Cabungcal, J.-H., Kulak, A., Kraftsik, R., Chen, Y., Dalton, T. P., Cuenod, M., & Do, K. Q. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3857-09.2010 · Cited by 202
Ketamine and phencyclidine: the good, the bad and the unexpected
Lodge, D., & Mercier, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13222 · Cited by 197
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk
Barron, H., Hafizi, S., Andreazza, A. C., & Mizrahi, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030651 · Cited by 183
Cadinu, D., Grayson, B., Podda, G., Harte, M., Doostdar, N., & Neill, J. C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.045 · Cited by 169
Downregulation of Parvalbumin at Cortical GABA Synapses Reduces Network Gamma Oscillatory Activity
Volman, V., Behrens, M. M., & Sejnowski, T. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3041-11.2011 · Cited by 164
Powell, S. B., Sejnowski, T. J., & Behrens, M. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.049 · Cited by 164
Behrens, M. M., & B, T. J. S. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 163
NMDAR Hypofunction Animal Models of Schizophrenia
Lee, G. S., & Zhou, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00185 · Cited by 168
Modelling prefrontal cortex deficits in schizophrenia: implications for treatment
Pratt, J. A., Winchester, C. L., Egerton, A., Cochran, S., & Morris, B. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.24 · Cited by 154
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Zamberletti, E., Beggiato, S., Steardo, L., Prini, P., Antonelli, T., Ferraro, L., Rubino, T., & Parolaro, D. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.028 · Cited by 147
Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models
O'Donnell, P. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr028 · Cited by 145
The Role of Parvalbumin Interneurons in Neurotransmitter Balance and Neurological Disease
Nahar, L., Delacroix, B. M., & Nam, H. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.679960 · Cited by 126
Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
Nakazawa, K., Jeevakumar, V., & Nakao, K. (2017) · npj Schizophrenia · doi:10.1038/s41537-016-0003-3 · Cited by 110
Cortical Oscillations in Health and Disease
Traub, R. D., & Whittington, M. A. (2010) · doi:10.1093/acprof:oso/9780195342796.001.0001 · Cited by 108
Parellada, E., & Gassó, P. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01385-9 · Cited by 108
Thomases, D. R., Cass, D. K., & Tseng, K. Y. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4147-12.2013 · Cited by 89
Jiang, Z., Cowell, R. M., & Nakazawa, K. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00116 · Cited by 91
Wieck, A., Andersen, S. L., & Brenhouse, H. C. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.11.012 · Cited by 88
Shah, A., & Lodge, D. J. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.145 · Cited by 87
Models of Neurodevelopmental Abnormalities in Schizophrenia
Powell, S. B. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_57 · Cited by 87
Dong, X., Zhang, W., Wang, H.-X., Stradtman, G. G., & Gao, W. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570900042x · Cited by 84
Tse, M., Piantadosi, P. T., & Floresco, S. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.007 · Cited by 77
Sun, H., & Neugebauer, V. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00762.2010 · Cited by 71
Inhibitory Interneurons, Oxidative Stress, and Schizophrenia
Sullivan, E. M., & O'Donnell, P. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs052 · Cited by 71
Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats
François, J., Ferrandon, A., Koning, E., Angst, M.-J., Sandner, G., & Nehlig, A. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709009985 · Cited by 68
Mice with genetically altered glutamate receptors as models of schizophrenia: A comprehensive review
Inta, D., Monyer, H., Sprengel, R., Meyer‐Lindenberg, A., & Gass, P. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.010 · Cited by 67
Neurodevelopmental Animal Models of Schizophrenia: Role in Novel Drug Discovery and Development
Wilson, C., & Terry, A. V. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.2.4 · Cited by 70
Sex differences in animal models of schizophrenia shed light on the underlying pathophysiology
Hill, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.10.014 · Cited by 61
Gilabert‐Juan, J., Bellés, M., Sáez-Ibáñez, A. R., Carceller, H., Zamarbide-Forés, S., Moltó, M. D., & Nácher, J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.07.008 · Cited by 56
Gaskin, P. L. R., Alexander, S. P. H., & Fone, K. C. F. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3424-y · Cited by 57
du Bois, T. M., Deng, C., Han, M., Newell, K. A., & Huang, X. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.002 · Cited by 50
Bartley, A. F., Lucas, E. K., Brady, L. J., Li, Q., Hablitz, J. J., Cowell, R. M., & Dobrunz, L. E. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1834-15.2015 · Cited by 54
Geddes, A. E., Huang, X., & Newell, K. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.017 · Cited by 52
Grayson, B., Barnes, S. A., Markou, A., Piercy, C., Podda, G., & Neill, J. C. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_403 · Cited by 51
Wang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
NMDA receptor-dependent function and plasticity in inhibitory circuits
Moreau, A. W., & Kullmann, D. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.004 · Cited by 44
Coleman, L. G., Jarskog, L. F., Moy, S. S., & Crews, F. T. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.04.017 · Cited by 43
Cardis, R., Cabungcal, J.-H., Dwir, D., Kim, Q., & Steullet, P. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.10.006 · Cited by 45
Lodge, D. J., & Perez, S. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s42708 · Cited by 42
Gaskin, P. L. R., Toledo‐Rodriguez, M., Alexander, S. P. H., & Fone, K. C. F. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw062 · Cited by 44
Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life
du Bois, T. M., Newell, K. A., & Huang, X. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.002 · Cited by 39
Ji, M., Wang, Z., Sun, X., Tang, H., Zhang, H., Jia, M., Qiu, L.-L., Zhang, G.-F., Peng, Y. G., & Yang, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9943-x · Cited by 39
Fitzgerald, M. L., Mackie, K., & Pickel, V. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.021 · Cited by 38
Li, J.-T., Zhao, Y., Wang, H.-L., Wang, X.-D., Su, Y., & Si, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.003 · Cited by 37
Nomura, T., Oyamada, Y., Fernandes, H. B., Remmers, C. L., Xu, J., Meltzer, H. Y., & Contractor, A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.012 · Cited by 40
Hickey, A. J., Reynolds, J. N., & Beninger, R. J. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.015 · Cited by 38
Shepard, R. M., Heslin, K. A., Hagerdorn, P. L., & Coutellier, L. D. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0436-3 · Cited by 39
Postnatal exposure to MK801 induces selective changes in GAD67 or parvalbumin
Turner, C. P., DeBenedetto, D., Ware, E., Stowe, R. C., Lee, A. J., Swanson, J. M., Walburg, C., Lambert, A., Lyle, M. A., Desai, P., et al. (2009) · Experimental Brain Research · doi:10.1007/s00221-009-2059-z · Cited by 33
Local injection of MK801 modifies oscillatory activity in the nucleus accumbens in awake rats
Hunt, M. J., Falińska, M., & Kasicki, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102539 · Cited by 35
Wang, H.-X., & Gao, W. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.024 · Cited by 33
Hasam‐Henderson, L. A., Gotti, G. C., Mishto, M., Klisch, C., Gerevich, Z., Geiger, J. R. P., & Kovács, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-27830-2 · Cited by 34
Toriumi, K., Oki, M., Muto, E., Tanaka, J., Mouri, A., Mamiya, T., Kim, H., & Nabeshima, T. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4288-8 · Cited by 31
Leppä, E., Linden, A.-M., Vekovischeva, O. Y., Swinny, J. D., Rantanen, V., Toppila, E., Höger, H., Sieghart, W., Wulff, P., Wisden, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024159 · Cited by 30
Alherz, F. A., Alherz, M., & Almusawi, H. M. (2017) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2017.02.001 · Cited by 32
Burstein, E. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00836-7 · Cited by 31
Secher, T., Berezin, V., Bock, E., & Glenthoj, B. Y. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.012 · Cited by 29
Dong, C., Rovnaghi, C. R., & Anand, K. J. S. (2016) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12689 · Cited by 29
Joshi, D., Catts, V. S., Olaya, J. C., & Weickert, C. S. (2015) · Schizophrenia · doi:10.1038/npjschz.2014.4 · Cited by 28
Perez, S. M., Aguilar, D. D., Neary, J. L., Carless, M. A., Giuffrida, A., & Lodge, D. J. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.169 · Cited by 27
Broberg, B. V., Oranje, B., Glenthoj, B. Y., Fejgin, K., Plath, N., & Bastlund, J. F. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.04.026 · Cited by 27
Ghoshal, A., Moran, S. P., Dickerson, J. W., Joffe, M. E., Grueter, B. A., Xiang, Z., Lindsley, C. W., Rook, J. M., & Conn, P. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00167 · Cited by 25
Fujihara, K., Yamada, K., Ichitani, Y., Kakizaki, T., Jiang, W., Miyata, S., Suto, T., Kato, D., Saito, S., Watanabe, M., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01108-6 · Cited by 30
5-HT6 Receptor Ligands and their Antipsychotic Potential
Arnt, J., & Olsen, C. K. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-385902-0.00006-1 · Cited by 26
Li, J., Su, Y., Wang, H., Zhao, Y., Liao, X.-M., Wang, X., & Si, T. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00017 · Cited by 26
Smith, K. M., Maragnoli, M. E., Phull, P. M., Tran, K. M., Choubey, L., & Vaccarino, F. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103696 · Cited by 26
Chen, L., Perez, S. M., & Lodge, D. J. (2014) · Developmental Neurobiology · doi:10.1002/dneu.22172 · Cited by 25
Elsworth, J. D., Groman, S. M., Jentsch, J. D., Léránth, C., Redmond, D. E., Kim, J. D., Diano, S., & Roth, R. H. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu048 · Cited by 23
Long, L. E., Anderson, P., Frank, E., Shaw, A. D., Liu, S., Huang, X., Pinault, D., Karl, T., O'Brien, T. J., Weickert, C. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124114 · Cited by 23
Radonjić, N. V., Jakovčevski, I., Bumbasirevic, V. Z., & Petronijević, N. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2999-7 · Cited by 22
Gutierrez, S., Carnes, A., Finucane, B., Musci, G., Oelsner, W., Hicks, L., Russell, G. B., Liu, C., & Turner, C. P. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.03.016 · Cited by 22
Krystal, J. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.011 · Cited by 22
Beninger, R. J., Beuk, J., Banasikowski, T. J., van Adel, M., Boivin, G. A., & Reynolds, J. N. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283347091 · Cited by 21
Kjærby, C., Bundgaard, C., Fejgin, K., Kristiansen, U., & Dalby, N. O. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.041 · Cited by 24
Decreased parvalbumin immunoreactivity in the cortex and striatum of mice lacking the CB1 receptor
Fitzgerald, M. L., Lupica, C. R., & Pickel, V. M. (2011) · Synapse · doi:10.1002/syn.20911 · Cited by 20
Schiavone, S., Morgese, M. G., Bové, M., Colia, A. L., Maffione, A. B., Tucci, P., Trabace, L., & Cuomo, V. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109750 · Cited by 19
Martínez-Pinteño, A., García-Cerro, S., Mas, S., Torres, T., Boloc, D., Rodríguez, N., Lafuente, A., Gassó, P., Arnáiz, J. A., & Parellada, E. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.04.005 · Cited by 17
Developmental GABAergic deficit enhances methamphetamine-induced apoptosis
Abekawa, T., Ito, K., Nakato, Y., & Koyama, T. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2269-5 · Cited by 17
Liu, Y., Kong, L., Yu, Y., Zang, J., Zhang, L., Guo, R., Li, S., Cheng, L., Li, X., & Chen, Y.-Q. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s470219 · Cited by 16
Riordan, A. J., Schaler, A. W., Fried, J., Paine, T. A., & Thornton, J. E. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.024 · Cited by 20
Rajagopal, L., Huang, M., Michael, E., Kwon, S., & Meltzer, H. Y. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0160-3 · Cited by 16
Kim, S. H., Park, H. G., Kim, H. S., Ahn, Y., & Kim, Y. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991192 · Cited by 15
Jones, K. S., Corbin, J. G., & Huntsman, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109303 · Cited by 15
Optimized CLARITY technique detects reduced parvalbumin density in a genetic model of schizophrenia
Bastrup, J., & Larsen, P. H. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.03.011 · Cited by 18
Honeycutt, J. A., & Chrobak, J. J. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.031 · Cited by 15
Olivares-Berjaga, D., Martínez-Pinteño, A., Rodríguez, N., Mas, S., Morén, C., Parellada, E., & Gassó, P. (2025) · Translational Psychiatry · doi:10.1038/s41398-024-03194-2 · Cited by 12
Metadata
- Authors
- Wang, C. Z., Yang, S. F., Xia, Y., & Johnson, K. M.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Wang, Cheng Z
- Johnson, Kenneth M
- ORCID
- Xia, Yan
- Venue
- Neuropsychopharmacology
- Published
- 2007-12-05
- Volume
- 33
- Issue
- 10
- Pages
- 2442-2455
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2026782090
- Cited by
- 161
- References
- 110
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 9 · 2018: 6 · 2017: 9 · 2016: 6 · 2015: 13 · 2014: 13 · 2013: 11 · 2012: 7
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- University of Texas Medical Branch
- National Institutes of Health (5r01mh063871-04)
- National Institute of Mental Health (MH63871)
- National Institute on Drug Abuse (DA 02073, R01DA002073)
- Topics
- Life Sciences › Neuroscience › Developmental Neuroscience › Anesthesia and Neurotoxicity Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- phencyclidine, NMDA receptor blockade, parvalbumin interneurons, calretinin, calbindin, GABAergic interneurons, schizophrenia model, postnatal drug exposure, caspase-3, TUNEL, somatosensory cortex, motor cortex, retrosplenial cortex
- MeSH terms
- Animals, Animals, Newborn, Bromodeoxyuridine, Cell Count, Cell Survival, Cerebral Cortex, Disease Models, Animal, Female, Interneurons, Male, Parvalbumins, Phencyclidine, Schizophrenia, Time, Rats, Sprague-Dawley, Apoptosis, Excitatory Amino Acid Antagonists, Cell Proliferation, Rats, Caspase 3, Calbindins, S100 Calcium Binding Protein G, Calbindin 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review